Mumbai-based pharma major Cipla Ltd closed at ₹1,256.80 on March 19, 2026, marking a new 52-week low of ₹1,243.80 after a 0.92% decline. The stock has now breached its previous low of ₹1,264.60 set just a day earlier (18 March 2026), continuing a multi-day downtrend that has seen it shed value despite the broader Nifty's resilience.
This fresh yearly low comes amid persistent pressure on large-cap pharmaceutical names, with peers like Sanofi and PGHH also testing or breaching their 52-week lows in recent sessions. Investors remain cautious on near-term earnings visibility and margin outlook in the sector.
Cipla now trades well below its recent range and faces immediate technical support near ₹1,200–1,220 levels.
Key Takeaways
- Large-cap defensives and consumer names (CIPLA, PGHH, COLPAL, BATAINDIA, SANOFI) continued to test yearly lows, reflecting sector rotation and profit booking.
- Momentum was concentrated in select mid- and small-caps (SIGMAADV, RMDRIP, WAAREEINDO, APSISAERO) that locked upper circuits with solid volumes.
- Lower-circuit action remained intense in micro-cap and penny space, with OSIAHYPER seeing the heaviest participation.
Nifty faces key resistance near 24,000–24,100 while support is visible around 23,600–23,500 levels. Traders should remain watchful of stock-specific moves in this divergent environment.
